Comparison · NCT00772941-dc104cc2
Administration Prolonged After 12 Weeks vs Administration Not Prolonged After 12 Weeks: Risk Factors for the Proportion of Responders - Prolonged Administration After 12 Weeks.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Administration Prolonged After 12 Weeks vs Administration Not Prolonged After 12 Weeks: Risk Factors for the Proportion of Responders - Prolonged Administration After 12 Weeks. Trial comparisons, record NCT00772941-dc104cc2. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00772941-dc104cc2
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.609 | 0.487 | 0.719 | wilson | |
| Risk in group 2 | 0.787 | 0.77 | 0.802 | wilson | |
| Risk difference, group 1 minus group 2 | -0.177 | -0.301 | -0.0658 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.775 | 0.636 | 0.944 | log | |
| Odds ratio, group 1 over group 2 | 0.423 | 0.254 | 0.706 | log | |
| Number needed to treat, for one fewer participant with the outcome on Administration Prolonged After 12 Weeks than on Administration Not Prolonged After 12 Weeks | 5.65 | 3.33 | 15.2 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Administration Prolonged After 12 Weeks | Participants with prolonged administration of Varenicline after 12 weeks according to Japanese Package Insert. | 39 | 64 | OG000 |
| Group 2 | Administration Not Prolonged After 12 Weeks | Participants without prolonged administration of Varenicline after 12 weeks according to Japanese Package Insert. | 1,993 | 2,534 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Risk Factors for the Proportion of Responders - Prolonged Administration After 12 Weeks.
- Description
The primary analysis item was the number of participants succeeding with continuous smoking cessation for the previous 4 weeks/the number of participants for efficacy evaluation excluding drop-out participants.
- Time frame
- 24 weeks
- Population
The efficacy analysis population basically consists of the evaluable participants in accordance with the separately prepared analysis plan (participants judged to have been evaluated appropriately). The number of participants in whom the prolonged administration of Varenicline after 12 weeks was confirmed was 2598.
Source ClinicalTrials.gov
Trial
- Title
- Drug Use Investigation Of Varenicline (Regulatory Post Marketing Commitment Plan)
- NCT number
- NCT00772941
- Phases
- Conditions
- Smoking Cessation
- Interventions
- Varenicline
- Lead sponsor
- Pfizer
- Results first posted
- 2014-01-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00772941?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00772941-dc104cc2